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Stratified Medicine (SM) has the potential to target patient populations who will most ben-
efit from a therapy while reducing unnecessary health interventions associated with side
effects.The link between clinical biomarkers/diagnostics and therapies provides new oppor-
tunities for value creation to strengthen the value proposition to pricing and reimbursement
(P&R) authorities. However, the introduction of SM challenges current reimbursement
schemes in many EU countries and the US as different P&R policies have been adopted
for drugs and diagnostics. Also, there is a lack of a consistent process for value assess-
ment of more complex diagnostics in these markets. New, innovative approaches and more
flexible P&R systems are needed to reflect the added value of diagnostic tests and to stim-
ulate investments in new technologies. Yet, the framework for access of diagnostic-based
therapies still requires further development while setting the right incentives and appro-
priate align stakeholders interests when realizing long-term patient benefits. This article
addresses the reimbursement challenges of SM approaches in several EU countries and
the US outlining some options to overcome existing reimbursement barriers for stratified
medicine.
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INTRODUCTION
Stratified medicine (SM) represents a novel approach to increase
pharmaceutical and biopharmaceutical R&D efficiency and to pro-
vide improved medical outcomes for the patient and the health
care system. Matching therapies to patient populations using
clinical biomarker/diagnostics based SM offers the prospect to
enhance patient care with safer and more effective drugs, deliv-
ered with a greater probability of treatment success. The link
between clinical biomarkers and preventive or curative thera-
pies provides new opportunities for value creation, offers the
potential to change well-established clinical practices and to
strengthen the value proposition to pricing and reimbursement
(P&R) authorities.
While the SM approach has drawn great attention in the
medical community and the industry, there have been only a
few clinical and public health applications in SM to date (Gar-
rison et al., 2007; Blair, 2010; Meckley and Neumann, 2010).
Often named examples are: HER2/neu – Herceptin, KRAS/EGFR –
Vectibix and Erbitux, predictive for efficacy; UGT1A1/Irinotecan,
HLA-5701/Ziagen (HIV), predictive for safety; Oncotype DX and
MammaPrint prognostic for adjuvant chemotherapy. Industry is
moving slowly to use biomarkers and companion diagnostics in
routine clinical practice despite scientific advances and increasing
investments in the biomarker-related research and development
(Davis et al., 2009; Tufts Center for the Study of Drug Devel-
opment, 2010). Scientific barriers, concerns about the economic
viability of the SM business case and difficulties in securing cov-
erage and adequate reimbursement in various markets are main
reasons mentioned.
Although there is a push from health care authorities (FDA1,
EMA2) and payers toward stratification, the application of bio-
markers and companion diagnostics to drug development and
commercialization is occurring in a complex legal, regulatory,
and reimbursement environment. Diagnostics and pharmaceu-
ticals are evaluated by different decision makers within the health
authorities, whereas a holistic approach is required in order to
assess the full health- and economic value of SM. Third party
payers in various healthcare systems have been rather resistant to
paying for costly stratification diagnostics unless the diagnostic
companies can demonstrate clinical utility and cost-effectiveness
without endangering the various health care budgets. At the
same time, third party coverage and adequate reimbursement are
essential to providing beneficiary access to patient care and to
encouraging continued investments in SM interventions.
This paper will discuss the reimbursement challenges of SM
approaches in several EU countries and the US. Required changes
and options to overcome existing reimbursement barriers for SM
will be outlined.
CONCEPT STRATIFIED MEDICINE AND REIMBURSEMENT
CHALLENGES
CONCEPT STRATIFIED MEDICINE
Stratified medicine as opposed to empirical medicine is the prac-
tice of using biomarkers or diagnostic tests to guide the choice of
1http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.
htm
2http://www.ema.europa.eu/ema/
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therapeutic treatments (Trusheim et al., 2007). In the SM case,
a predictive diagnostic test stratifies the patient population to
responders and non-responders for a certain treatment,whereas by
contrast, in empirical medicine all patients would receive the same
treatment (Goren, 2007). This approach of proactively testing
and selecting populations for specific treatments aims at ensuring
increased efficacy and/or reduce toxicity, but at the same time it
reduces the eligible patient population. Advances in understanding
the mechanisms underlying diseases, as well as drug response, cre-
ate opportunities to match patients with therapies that are more
likely to be effective and safe. At the extreme of patient match-
ing are “individualized” medicines, which vary inherently for each
patient such as cancer vaccines that are based on a particular
patient’s tumor, representing one end of a continuum (Figure 1).
Empirical medicine is at the other end of this continuum
where some agents, such as non-steroidal anti-inflammatory drugs
(NSAIDs) work for a large group of patients. In between lies
the field of SM, in which a patient can be found to be similar
to a cohort that has historically shown a differential therapeu-
tic response to a particular therapy using a clinical biomarker.
For example, the anticancer drug trastuzumab (Herceptin) shows
superior efficacy in breast cancer patients with HER2/neu-positive
cancer (expressed in 25–30% of breast cancer patients).
Stratified medicine adds a further step to traditional clinical
practice in which a clinical biomarker is evaluated to associate a
patient with a specific therapy. The identification of clinical bio-
markers or diagnostics linked to the gene expression profile of
individual or sub-populations of patients is an essential feature of
SM. Trusheim et al. (2007) consider clinical biomarkers to include
any diagnostic test or clinical observation that indicates a preferred
or contraindicated treatment for a specific patient subpopulation.
Such tests can be based on gene expression patterns, individual
proteins, proteomic patterns, metabolomics, histology, imaging,
physicians’ clinical observations, and even self-reported patient
surveys. In other words, they define a clinical biomarker not by its
technology or biological basis, but rather by its reliable, predictive
correlation to differential patient responses. However, the identifi-
cation of valid, reproducible associations between genetics, disease
progression, and/or treatment response is challenging in the clin-
ical R&D process and implies a good understanding of the mole-
cular mechanisms which causes the disease as well as appropriate
studies to identify genetic variants correlated with drug response.
Today, some therapeutic areas include SM approaches and oth-
ers do not, as at least three specific criteria (Douglas, 2008) will be
necessary for the emergence of a clinical relevant patient subclass
and consequent SM. These criteria include the presence of: differ-
ential biological mechanisms, different treatment options, and a
biological marker or diagnostic.
Stratified medicine is practiced in several contexts within the
healthcare industry and a shift from “one-size-fits-all” to a tailored
approach is already impacting the development of new products.
Pharmaceutical and biopharmaceutical industry is using biomark-
ers as predictors of efficacy and safety to discover new targets and
to achieve a differential patient response to therapy helpings to
improve the efficiency of compound attrition and R&D produc-
tivity over time. Today between 12 and 50% of current clinical
pipelines of leading pharmaceutical and biotechnology companies
(21 assessed) involves SM, and between 2006 and 2010, the invest-
ment of this industry in SM/biomarker research increased by a
mean of 75%, with and additional increase of 53% predicted by
2015 (Tufts Center for the Study of Drug Development, 2010).
In some cases, industry is developing these markers as compan-
ion diagnostic test (e.g., co-developed with a diagnostic company)
to identify patient sub-populations most likely to benefit from a
particular therapy. For instance, trastuzumab (Herceptin) used
a HER2 overexpression test as a predictive marker to increase
efficacy in the responder patient population and has achieved
blockbusters status. Also, cetuximab (Erbitux) and panitumumab
(Vectibix) have benefited from KRAS companion diagnostic test
predictive for efficacy in colorectal cancer patients and KRAS
testing became mandatory for certain EGFR-kinase-targeted ther-
apies. HLA-B∗5701 genetic testing predicts hypersensitivity to aba-
cavir (Ziagen) and found widespread acceptance in the HIV/AIDS
treatment to be responsible for the resurgence of this drug in the
market. In other cases, SM tests being developed post hoc by diag-
nostic companies as a way of personalizing an existing drug (e.g.,
metabolic potential of Warfarin to guide dosing) or as stand-alone
tests (e.g., Oncotype DX) for diagnostic or prognostic purposes.
STRATIFIED MEDICINE CHALLENGES CURRENT REIMBURSEMENT
SCHEMES IN EU AND THE US
Third party payers in public and private health care systems in
EU and the US have adopted different P&R policies for drugs and
diagnostics. While P&R of pharmaceuticals in many EU countries
and the US can be characterized as somewhat “value-based,” the
reimbursement of diagnostics is resource or cost-based (Garrison
and Austin, 2006). For instance, laboratory-based in vitro diagnos-
tic tests have traditionally been treated as low-margin commodity
FIGURE 1 | Stratified medicine diagram (adapted from:Trusheim et al., 2007,The patient therapeutic continuum).
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items in many markets with rather low reimbursement rates which
are solely based on the method of test (e.g., immunoassay) and not
according to the value the tests brings to the patient.
Reimbursement agencies across Europe have compiled lists
of devices and procedures which are generally based on the
diagnostic-related group (DRG) system (e.g., in Germany G-DRG;
France/GHS code). In this system, similar and related medical pro-
cedures are grouped together. Each group is then coded and given
a monetary value, which is the set amount of money that will be
reimbursed for each procedure. In the US, all in vitro diagnostic
must be assigned to Current Procedural Terminology (CPT) code
in order to be reimbursed.
Major payers and other health authorities will make an effort
to link new diagnostic to the existing reimbursement level of
older tests involving similar effort and cost. This means, that pay-
ments must come from an existing budget set for procedure based
inpatient DRG’s or linked to out-patients codes set.
To command higher prices for a more complex diagnostic out-
side the global caps of these procedures will be both challenging
and time-consuming in various countries. Currently, there is no
clear or consistent process for value assessment of more com-
plex diagnostics established in the EU and the US. Standards and
mechanisms such as with AMCP Format in the US and health
technology assessment (HTA) with NICE in the UK do not exist
in the same way for diagnostics in Western EU countries and the
US. Instead, reimbursement of diagnostics in these markets is set
on a case-by-case basis where diagnostic tests in most EU coun-
tries are reviewed at the local or regional level, and in the US, for
example with Medicare, as a combination of national and local
jurisdictions.
Only in few examples of companion diagnostic tests, there have
been HTA’s in some EU countries (e.g., NICE for HER2, EGFR,
and KRAS testing) often followed by cumbersome reimburse-
ment negotiations and resulting in a cost-based funding of the
test (Miller et al., 2011). Moreover, in some countries (e.g., UK,
Spain) market access for these diagnostic based therapies have
been achieved only through subsidizations for the diagnostic tests
(lower test prices/or free test) by pharmaceutical manufactures.
There are challenges to determine the clinical and economic
value of more complex stand-alone or companion diagnostics.
Often there are scientific barriers, such as lack of data that links
interventions to health outcomes and costs and that provides com-
parison to alternative approaches. For a diagnostic test to be useful
in clinical practice, it must provide reliable, actionable, and pre-
dictive information to a clinician’s treatment recommendation
(Deverka et al., 2010). However, in clinical practice, the strength of
evidence from simple diagnostic test to rather complex molecular
diagnostic test varies widely across types of diagnostics technol-
ogy. Often, tests are developed to prove clinical validity (sensitivity
and specificity of the test) without evaluating clinical utility. Also,
case-control, observational, and patient cohort studies are used to
determine the clinical value of biomarker based diagnostic when
randomized control trials (RCT) are not feasible or too expen-
sive (Scott, 2010). Furthermore, different payers (regional, budget
holder) have different evidence requirements (prospective, retro-
spective) for what is sufficient to determine the clinical utility of a
diagnostic test.
There is a significant need to clarify the evidentiary frame-
work of the payers concerning specific characteristics from simple
versus complex molecular test for separate development versus
co-development. Organizations such as the Center for Medical
Technology Policy (CMTP) and the Evaluation of Genomic Appli-
cations in Practice and Prevention (EGAPP) in the US as well
as the European Personalized Medicine Diagnostics Association
are working to explore evidentiary criteria for reimbursement to
increase transparency on coverage decisions and to provide indus-
try some guidance when making their decisions to develop innov-
ative diagnostic products (Tunis, 2008). In addition, there are on-
going projects from the European Commission such as IT-Future
of Medicine (ITFoM) to build a “personalized patient model” and
regional initiatives (e.g., DEMOTEK from Basque country) aimed
at helping to facilitate the introduction of innovative technologies
developed by the local industry.
Directly linked to the quality of clinical evidence there are chal-
lenges in determining the economic value of SM interventions.
Although many observers have discussed the potential economic
value of SM approaches there is currently limited empirical evi-
dence available supporting such claims (Issa, 2007). To date, a few
cost-effectiveness analyses exist for SM interventions with incon-
clusive results as the evidence for effectiveness is frequently prelim-
inary or hypothetical. A recent review by Wong et al. (2010) which
examined the economic literature for pharmacogenomics, found
34 economic evaluations where only for two biomarkers there
was sufficient evidence supporting both clinical validity and util-
ity, allowing a true cost-effectiveness analysis. The lack of reliable
information was also reinforced by a former systematic review of
pharmacogenetic and genomic interventions byVegter et al. (2008)
which may explain why currently such cost-effectiveness analyses
have little influence on reimbursement decisions in many markets.
To realize the promise of SM approaches there is a need to
perform economic evaluations which take into consideration the
full impact of using such an intervention on the whole treatment
pathway of patients including disease prevention. But in contrast,
in many health care systems in Western EU countries and the US
there is no longitudinal accounting which would enable payers to
capture long-term cost savings from near-term testing. However,
anticipated health care costs savings from targeting drug ther-
apy will remain theoretical until a more holistic perspective on
healthcare may be followed (Deverka et al., 2010).
Many observers have emphasized the need for more flexible
P&R systems which stimulate and reward innovations and reflect
the added value of diagnostic tests. Garrison and Austin, see value-
based, flexible reimbursement systems for innovative, patent-
protected diagnostic being critical to create stronger economic
incentives for the development of SM approaches. Seiguer (2007)
also concluded that there is hardly any incentive for industry to
invest in companion diagnostics unless diagnostics can capture
adequate value of diagnostics. Several government commissioned
reports have recommended a re-evaluation of reimbursement
rates for diagnostics (PCAST, 2008; SACGHS, 2008) by pursu-
ing changes in diagnostic coding and payment systems to better
reflect the value of diagnostic tests. However, changing standard
coverage principles and/or to establish new coding systems is a
rather long-term process in many EU countries and the US.
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In the meantime, novel payment approaches, risk sharing, and
conditional reimbursement agreements with third party payers are
explored to overcome the tension between funding new but expen-
sive technologies and obtaining value for money where traditional
reimbursement is not deemed appropriate. These arrangements
between a manufacturer and payer/provider can use a variety of
mechanisms (e.g., pay-for-performance, value-based purchasing)
to address uncertainty about the real performance of technologies
in daily practice enabling certain market access. They can help
to enhance the value of SM on a case-by-case basis and may pro-
vide incentives for the Diagnostic industry to generate high quality
clinical and health economic evidence. However, in practice there
are many organizational and implementation challenges to over-
come to ensure effectiveness of such agreements including the
need for a strong collaboration between Pharmaceutical/Biotech
and the Diagnostic industry by addressing value sharing issues for
companion diagnostic in particular.
Finally, reimbursement authorities are concerned not only with
the performance characteristics of new medical diagnostic but also
in its feasibility to implement it in a service setting (McCabe et al.,
2009). Beside of the availability of appropriate infrastructure, the
development, adoption, and the use of medical diagnostics will
be influenced by health care provider competence in using these
technologies.
CONCLUSION AND FUTURE PERSPECTIVE
Stratified medicine can offer the potential to target patient pop-
ulations who will most benefit from a therapy while reducing
unnecessary health interventions associated with side effects and
thus, may demonstrate a differential value proposition in order to
gain substantial market access. Multiple studies have shown that
most drugs prescribed in various diseases are effective in fewer
than 60% of treated patients (e.g., oncology only 25–30%) outlin-
ing the potential to realize efficiency gains for healthcare systems
(Aspinall, 2007).
Medical diagnostics is fundamentally about identifying the
subgroups of patients, however, in clinical practice, many of the
available tests do not demonstrate clinical utility which makes it
difficult to demonstrate the value of diagnostics.
Market Access of SM approaches depends much on the assess-
ment process, in particular HTA and P&R decisions. Today,
fragmentation of HTA data requirements and methodology but
also of P&R systems for diagnostic testing which are primarily
cost/procedure based are not necessarily structured to reward the
added value of using tests to improve health outcomes. Novel pay-
ment approaches and risk sharing agreement may help to enhance
the value of SM interventions on a case-by-case basis provided
that clinical and health economics outcomes are transparent.
Generating high quality clinical and health economic evidence
will provide the confidence that enables payers more rapidly to
adopt tests. At the same time, payer decision making may need
to become flexible enough to allow for short-term inefficiencies
in order to understand and benefit from long-term value. While
the need for market access of diagnostic based therapies is not
questions, the framework for access while setting the right incen-
tives and appropriate alignment of stakeholder when realizing
long-term patient benefits still needs further development.
Fostering broader coverage of SM approaches within the
healthcare systems will require a more centralized, holistic, and
consistent process for conducting HTA’s in Europe and the US.
Commonly accepted standards and procedures on how to evalu-
ate stand-alone diagnostics and test treatment combinations may
provide industry with a clear-cut pathway to market access and
reimbursement for population-wide use (Postma et al., 2011). At
the same time, a more holistic approach to health care funding is
required in order to realize the full clinical and health economic
benefits of SM interventions. Because of silo mentality in many
health care systems, national authorities may need to develop a
central financial system specifically applied for SM interventions.
Recent emerging policy trends and health care financing reform
initiatives toward a more value-based healthcare will help to
enhance the value of SM approaches in clinical practice. There
is a need to take this further and ensure that core SM measures are
incorporated into the value-based reimbursement schemes.
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